Aumet is the back office of MENA's pharmacies.

A pharmacist in a side street off Mecca Road taps a phone at 6:47 a.m. She is ordering 38 SKUs from four different suppliers. Three years ago this took ninety minutes, a stack of WhatsApp threads, and at least one argument about a missing box of antihistamines. This morning it takes her four taps. The software doing the work in the background does not have a brand the customer would recognize. It is called Aumet, and a version of this scene is now playing out 5 million times a year.

That is the part that surprises people. Aumet is not a household name. It does not run TV spots. It does not have a flashy consumer app. What it has, increasingly, is the plumbing - the wholly unglamorous, wholly load-bearing plumbing - of how medicine moves through the Middle East. In May 2026, the company closed a $12 million Series A led by Emkan Capital. The cheque is the punctuation mark. The sentence has been quietly compounding for a decade.

01 - THE PROBLEMThe mess nobody wanted to digitize

Pharmaceutical procurement in MENA is, to put it generously, fragmented. A mid-size pharmacy chain in Cairo might buy from sixty distributors, some of whom still take orders by fax. A hospital in Amman might run an ERP that was state-of-the-art when Friends was on TV. Drug shortages move in waves, and nobody upstream can see them coming until shelves are empty. It is the kind of problem that consultants describe with the word "opportunity" and operators describe with the word "exhausting."

For years, the assumption was that the answer would arrive from outside - an Amazon-shaped solution airdropped onto a region whose supply chain politics it did not understand. That assumption aged badly. Regulation is local. Trust is local. The man who decides which distributor a pharmacy uses is often someone the pharmacist has known since pharmacy school. A marketplace that ignores those facts is a marketplace that ships zero boxes.

Above: the unromantic truth about MENA pharma logistics, in one sentence.

02 - THE BETThree founders, one stubborn idea

Yahya Aqel is a biomedical engineer. He spent the first part of his career around devices and decided the most interesting problem in healthcare was not a device at all - it was the invoice underneath it. Together with Adel Haddad, who later picked up an MBA at IE in Madrid, and co-founder Shahed Jaber, he started Aumet in 2016. The company was incorporated in Delaware, opened a French entity in 2017, and eventually planted its operational flag in Riyadh. Three passports, one thesis.

The thesis was unfashionable at the time. Marketplaces were having a moment. Aumet built one - and then almost immediately decided the marketplace alone was not the product. The product was the operating system around it. Inventory. Forecasting. Compliance. Payments. The boring middle of the supply chain, dressed in software a pharmacist could actually use at 6:47 a.m. without coffee.

03 - THE PRODUCTPulse, Chain, Enterprise

In 2025 Aumet did the thing every maturing software company eventually does: it rebranded its product line into something a salesperson could draw on a napkin. There are now three tiers. Pulse is for independent pharmacies and small clinics - digital procurement and inventory in a phone-shaped box. Chain is for pharmacy chains and distributors who need to manage a fleet of stores and a wall of suppliers. Enterprise is for ministries of health and national hospital networks, the buyers who can move a country's drug pricing by sneezing.

Underneath all three sits the AI layer Aumet has been training on its own transaction graph. The platform now does the unsexy things that matter: it predicts which SKUs a pharmacy will run out of next week, it routes orders to the supplier most likely to fulfil on time, it flags compliance risks before a regulator does. It is, in other words, behaving less like a marketplace and more like an exchange.

04 - THE PROOFWhat the numbers actually say

It is one thing to say a healthtech company is "scaling across MENA." It is another to put a ruler against it. The honest measurement of a procurement platform is not seats sold; it is gross merchandise value moved, transactions cleared, and shelves kept full. By those measures, Aumet is no longer a startup pitching a vision. It is a piece of infrastructure quietly carrying a load.

Above: a $1B-of-medicine company with a 160-person engineering room. The ratio is the story.

The Series A round itself is worth a closer look. Emkan Capital led. Qatar Development Bank, SABAH VC and AAIC Investment came in alongside existing backers Shorooq Partners and Right Side Capital Management. The shape of the cap table is, frankly, more interesting than its size. This is not pure venture money chasing a multiple. There is sovereign-flavoured capital in there, the kind that tends to show up when a company has crossed the line from "promising startup" to "regional asset."

05 - THE MISSIONRe-thinking healthcare, one PO at a time

Aumet's stated mission is to "re-think the healthcare business." It is the sort of phrase that arrives in every pitch deck and dies on most of them. What gives it teeth here is the choice of starting point. The company did not start with the patient. It did not start with the doctor. It started with the purchase order - the most ignored, least photogenic, most consequential document in the entire system.

If you fix the PO, you fix what reaches the shelf. If you fix what reaches the shelf, you fix what reaches the patient. The chain is short and unsentimental. Aumet has built its product roadmap and its values around it. Four stated principles - Openness, Shared Success, Antifragility, Hard Work - which read like a mission statement and behave, internally, like an org chart. Employee ownership is real. Engineering is largely remote. The cultural overhead is being kept deliberately thin so the company can keep absorbing new markets without buckling.

06 - WHY IT MATTERSThe next country, the next continent

There are two ways to read what Aumet is about to do next. The conservative reading: keep deepening Saudi, Jordan and Egypt; add a couple of GCC neighbours; turn into a profitable, defensible regional champion. The ambitious reading: take the AI procurement OS to every emerging market with the same shape of supply chain - which is most of them - and quietly become the back office of healthcare from Karachi to Kano.

Either way, the company has already done the hard part. It has earned the trust of regulators, pharmacists, distributors and sovereign-grade investors in a region where each of those constituencies has a long memory. The infrastructure has been laid. The data flywheel is turning. Whether or not the rest of the world ever learns the name "Aumet," it is increasingly likely to be using something Aumet built.

Back to the side street off Mecca Road. The pharmacist closes her phone. Thirty-eight SKUs, four distributors, four taps. The boxes will arrive before lunch. The customer who walks in at 9 a.m. asking for her grandfather's blood-pressure medication will get the right pack, the right strength, the right expiry date. She will not know that an AI in Riyadh decided, three weeks ago, that this pharmacy would need exactly this many of exactly this drug. She will not know the name Aumet. That is, more or less, the point.